ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

LPCN Lipocine Inc

4.7983
0.2483 (5.46%)
2024年4月27日 - 終了
15分遅延
名称 銘柄コード 市場 種別
Lipocine Inc LPCN NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
0.2483 5.46% 4.7983 06:46:57
始値 安値 高値 終値 前日終値
4.52 4.38 4.8099 4.7977 4.55
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/4/1120:00PRNUSLipocine Announces Positive LPCN 2401 Clinical Results..
2024/3/2821:00PRNUSLipocine Announces Positive Week 52 Results from LPCN 1148..
2024/3/2521:00PRNUSLipocine Announces First Cohort Dosed in Pivotal Study of..
2024/3/0807:31EDGAR2Form 8-K - Current report
2024/3/0722:00PRNUSLipocine Announces Financial Results for the Full Year Ended..
2024/3/0720:08EDGAR2Form 8-K - Current report
2024/3/0720:07EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
2024/3/0622:00PRNUSLipocine to Present at 36th Annual Roth Conference
2024/3/0620:01EDGAR2Form 8-K - Current report
2024/2/1306:10EDGAR2Form 8-K - Current report
2024/2/0622:00PRNUSLipocine Announces Confirmation of Dosing Regimen for..
2024/2/0222:00PRNUSLipocine Announces Continued Commercialization of TLANDO®..
2024/1/1822:20EDGAR2Form 8-K - Current report
2024/1/1822:00PRNUSLipocine and Verity Pharma Enter into License Agreement for..
2023/12/2000:00EDGAR2Form 8-K - Current report
2023/12/1922:00PRNUSLipocine to Present at Biotech Showcase 2024
2023/11/2306:15EDGAR2Form S-3 - Registration statement under Securities Act of..
2023/11/1404:45EDGAR2Form 8-K - Current report
2023/11/1404:45PRNUSLipocine Releases Late Breaking Presentation on LPCN 1148..
2023/11/0903:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/0823:50EDGAR2Form 8-K - Current report
2023/11/0822:00PRNUSLipocine Announces Financial Results for the Third Quarter..
2023/11/0122:31EDGAR2Form 8-K - Current report
2023/11/0121:00PRNUSLipocine to Present Clinical Data on LPCN 1148 at The Liver..
2023/10/2622:35EDGAR2Form 8-K - Current report
2023/10/2621:00PRNUSLipocine Completes Successful Meeting with FDA on LPCN 1154..
2023/10/2408:00PRNUSLipocine to Present at the H.C. Wainwright Annual NASH..
2023/10/0705:05EDGAR2Form 8-K - Current report
2023/9/2005:10EDGAR2Form 8-K - Current report
2023/9/2005:05PRNUSLipocine to Present at the Cantor Fitzgerald Global..
2023/8/1021:35EDGAR2Form 8-K - Current report
2023/8/1021:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/8/1021:00PRNUSLipocine Announces Financial Results for the Second Quarter..
2023/7/2719:45EDGAR2Form 8-K - Current report
2023/7/2719:30PRNUSLPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients..
2023/6/1421:00PRNUSLipocine to Present at H.C. Wainwright Annual..
2023/6/0721:00PRNUSLipocine to Present LPCN 1148 and LPCN 1144 at the EASL..
2023/5/1620:00PRNUSPositive Topline Clinical Results Support Streamlined..
2023/5/1119:00PRNUSLipocine Announces Financial Results for the First Quarter..

最近閲覧した銘柄

Delayed Upgrade Clock